Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06939127 | Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC | recruiting | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 |
| Apr 18, 2025 |
| clinicaltrials |
| NCT06557187 | Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC | active not recruiting | N/A | 40 | Yatian LiuOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06929390 | Comparing BTVA and MWA in COPD With Early Lung Cancer: Efficacy and Safety | not yet recruiting | N/A | 26 | Henan Provincial People's HospitalOTHER | 0 | Apr 18, 2025 | clinicaltrials |
| NCT06754930 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06926179 | Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer | recruiting | — | 500 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06930807 | Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer | recruiting | N/A | 1,000 | Peking University People's HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06537804 | Project Lung Cancer Screening in Southern Denmark(PLUS) | active not recruiting | N/A | 1,332 | Odense University HospitalOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06926803 | A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases | active not recruiting | — | 500 | Qiming WangOTHER_GOV | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06925048 | SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC | not yet recruiting | Phase 2 | 86 | Chunxia SuOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT06926413 | A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04654364 | Lung Cancer Registry | recruiting | — | 500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06921278 | Development of the Drug and Alcohol Respiratory Health Test(DARHT) | not yet recruiting | — | 260 | King's College LondonOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06921681 | Ultrasound-guided Cryobiopsy of Mediastinal/Hilar Lymph Nodes | recruiting | N/A | 136 | University of ZurichOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06922266 | Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option(Chewbacca) | not yet recruiting | — | 20 | Ospedale San RaffaeleOTHER | 0 | Apr 10, 2025 | clinicaltrials |
| NCT06621563 | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors(HS-20117) | recruiting | Phase 1 | 780 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06918782 | Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma | not yet recruiting | Phase 2 | 47 | The University of Hong KongOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT05389774 | DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution(DOLCE) | recruiting | — | 2,000 | Nottingham University Hospitals NHS TrustOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06829459 | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | recruiting | Phase 3 | 350 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05544240 | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 20 | Williams Cancer FoundationOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03290534 | Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet® | recruiting | Phase 2 | 40 | CivaTech OncologyINDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911606 | Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 2 | 45 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT01394679 | A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer | not yet recruiting | Phase 3 | 154 | Cell>Point LLCINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04624373 | Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc(CELTICS) | recruiting | — | 50 | University Hospital, ToulouseOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06900283 | Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer(FACT-L_Pred) | active not recruiting | — | 320 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06903117 | Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06908733 | Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC | not yet recruiting | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06909383 | Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study | not yet recruiting | Phase 2 | 41 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT04025541 | Analysis of Circulating Tumor Markers in Blood(ALCINA2) | recruiting | N/A | 992 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03457415 | Collection of Sputum and Labeling for Lung Cancer | recruiting | — | 500 | bioAffinity Technologies Inc.INDUSTRY | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06107608 | Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors(LIFE) | recruiting | N/A | 58 | Jules Bordet InstituteOTHER | 1 | Mar 31, 2025 | clinicaltrials |
| NCT06772363 | SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis | not yet recruiting | — | 200 | Fuzhou General HospitalOTHER | 1 | Mar 31, 2025 | clinicaltrials |
| NCT06775002 | SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type | not yet recruiting | — | 223 | Fuzhou General HospitalOTHER | 0 | Mar 31, 2025 | clinicaltrials |
| NCT06111807 | Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC(MRD-LUNG) | recruiting | — | 248 | University Medical Center GroningenOTHER | 3 | Mar 30, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04852588 | Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment | recruiting | N/A | 29 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06528418 | Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | recruiting | — | 10,000 | ChromX HealthINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06889467 | Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer | recruiting | — | 10 | Barzilai Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06896890 | Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 32 | Inhatarget TherapeuticsINDUSTRY | 3 | Mar 26, 2025 | clinicaltrials |
| NCT03978377 | Cardiopulmonary Toxicity of Thoracic Radiotherapy(CLARIFY) | recruiting | — | 320 | University Medical Center GroningenOTHER | 3 | Mar 25, 2025 | clinicaltrials |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06891183 | Percutaneous Thermal Ablation in Lung Tumors(Radiofrequency) | recruiting | N/A | 50 | Assiut UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06890182 | Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | not yet recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06885840 | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. | not yet recruiting | Phase 2 | 100 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05636969 | Multimodal Prehabilitation in Patients with Lung Cancer Undergoing Neoadjuvant Therapy | recruiting | N/A | 60 | Hospital Clinic of BarcelonaOTHER | 1 | Mar 19, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Apr 22, 2025source: clinicaltrials